Chemotherapy uses medicines to kill fast-growing cells (like cancer cells) or to keep them from dividing (which is how cancers grow). It is a systemic treatment. This means the medicines will travel ...

ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...

Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

Dr. Daniel P. Petrylak discusses the different types of bladder cancer and how treatment options may vary based on disease stage and type. Strategies for the treatment of bladder cancer may vary by ...

or on the link below. Non–muscle-invasive bladder cancer (NMIBC) comprises 75% of newly diagnosed bladder cancer and poses significant clinical challenges because of high recurrence and progression ...

(Reuters) - The U.S. Food and Drug Administration has approved Johnson & Johnson's drug delivery system for a type of bladder cancer, offering a potential surgery-free option for patients. The drug ...

Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR ...

Nearly 200,000 Americans are living with muscle-invasive bladder cancer (MIBC)—and after decades with few major advances, newly presented data may signal a turning point in how the disease is treated.

Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being over age 55. And the unfortunate reality is that women are often diagnosed at ...